The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey

Clinical and Translational Allergy

Volumn 5, Issue 1, 2015, Pages

  Price, David ^a   Scadding, Glenis ^b   Ryan, Dermot ^c,d   Bachert, Claus ^e   Canonica, G Walter ^f   Mullol, Joaquim ^g   Klimek, Ludger ^h   Pitman, Richard ⁱ   Acaster, Sarah ^j   Murray, Ruth ^k   Bousquet, Jean ^l,m,n,o  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ROYAL NATIONAL THROAT NOSE AND EAR HOSPITAL   (United Kingdom)

^c Woodbrook Medical Centre   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f UNIVERSITY OF GENOA   (Italy)

^g INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^h Center for Rhinology and Allergology   (Germany)

ⁱ ICON Clinical Research   (United Kingdom)

^j Acaster Consulting   (United Kingdom)

^k Medscript Ltd   (Ireland)

^l MONTPELLIER UNIVERSITY HOSPITAL   (France)

^m MACVIA LR   (France)

ⁿ UMR S 1168   (France)

^o LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

more..

Author keywords

Absenteeism; Allergic rhinitis; Co medication; Presenteeism; Symptom episode; UK

Indexed keywords

ANTAZOLINE; AZELASTINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; HISTAMINE H1 RECEPTOR ANTAGONIST; LODOXAMIDE TROMETAMOL; OLOPATADINE; OXYMETAZOLINE; XYLOMETAZOLINE;

ABSENTEEISM; ADULT; ARTICLE; COMORBIDITY; CROSS-SECTIONAL STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG UTILIZATION; EPIPHORA; EYE REDNESS; FEMALE; HEALTH CARE NEED; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NASAL PRURITUS; NOSE OBSTRUCTION; OCULAR PRURITUS; PATIENT SATISFACTION; POLLEN ALLERGY; PRESENTEEISM; PRIORITY JOURNAL; RHINORRHEA; SNEEZING; UNITED KINGDOM;

EID: 85006100902     PISSN: None     EISSN: 20457022     Source Type: Journal    
DOI: 10.1186/s13601-015-0083-6     Document Type: Article

References (46)

1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8-160.
2. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007;62(Suppl 85):17-25.
3. Mullol J. A survey of the burden of allergic rhinitis in Spain. J Investig Allergol Clin Immunol. 2009;19:27-34.
4. Bousquet PJ, Demoly P, Devillier P, Mesbah K, Bousquet J. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol. 2013;160:393-400.
5. Canonica GW, Mullol J, Pradalier A, Didier A. Patient perceptions of allergic rhinitis and quality of life: findings from a survey conducted in europe and the United States. World Allergy Organ J. 2008;1:138-44.
6. Meltzer EO, Gross GN, Katial R, Storms WW. Allergic rhinitis substantially impacts patient quality of life: findings from the Nasal Allergy Survey Assessing Limitations. J Fam Pract. 2012;61:S5-10.
7. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. 2007;28:3-9.
8. European Academy of Allergy and Clinical Immunology (EAACI). Beware of Allergy Campaign. http://www.bewareofallergy.com. Accessed Aug 2015.
9. Antonescu E, Childres N, Gardini E, Grossetete F, Juvin P, Parvanova A, et al. Written declaration on recognising the burden of allergic disease. European Parliament. http://www.eaaci.org. Accessed June 2015.
10. Samolinski B, Fronczak A, Kuna P, Akdis CA, Anto JM, Bialoszewski AZ, et al. Prevention and control of childhood asthma and allergy in the EU from the public health point of view: Polish Presidency of the European Union. Allergy. 2012;67:726-31.
11. Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A, et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur Respir J. 2014;44:304-23.
12. Bousquet J, Michel J, Standberg T, Crooks G, Iakovidis I, Gomez M. The European Innovation Partnership on Active and Healthy Aging: the European Geriatric Medicine introduces the EIP on AHA Column. Eur Geriatr Med. 2014;5:361-2.
13. Valovirta E, Myrseth SE, Palkonen S. The voice of the patients: allergic rhinitis is not a trivial disease. Curr Opin Allergy Clin Immunol. 2008;8:1-9.
14. Kremer B, den Hartog HM, Jolles J. Relationship between allergic rhinitis, disturbed cognitive functions and psychological well-being. Clin Exp Allergy. 2002;32:1310-5.
15. Braido F, Baiardini I, Scichilone N, Musarra A, Menoni S, Ridolo E, et al. Illness perception, mood and coping strategies in allergic rhinitis: are there differences among ARIA classes of severity? Rhinology. 2014;52:66-71.
16. Green RJ, Davis G, Price D. Concerns of patients with allergic rhinitis: the Allergic Rhinitis Care Programme in South Africa. Prim Care Respir J. 2007;16:299-303.
17. Mullol J, Bartra J, del CA, Izquierdo I, Munoz-Cano R, Valero A. Specialist-based treatment reduces the severity of allergic rhinitis. Clin Exp Allergy. 2013;43:723-9.
18. Lamb CE, Ratner PH, Johnson CE, Ambegaonkar AJ, Joshi AV, Day D, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin. 2006;22:1203-10.
19. Hellgren J, Cervin A, Nordling S, Bergman A, Cardell LO. Allergic rhinitis and the common cold-high cost to society. Allergy. 2010;65:776-83.
20. Small M, Piercy J, Demoly P, Marsden H. Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey. Clin Transl Allergy. 2013;3:33.
21. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol. 2007;120:381-7.
22. Clatworthy J, Price D, Ryan D, Haughney J, Horne R. The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Respir J. 2009;18:300-5.
23. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy. 2007;62(Suppl 85):9-16.
24. Bousquet J, Annesi-Maesano I, Carat F, Leger D, Rugina M, Pribil C, et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy. 2005;35:728-32.
25. Bachert C, Van CP, Olbrecht J, van SJ. Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. Allergy. 2006;61:693-8.
26. Demoly P, Allaert FA, Lecasble M. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy. 2002;57:546-54.
27. Navarro A, Valero A, Rosales MJ, Mullol J. Clinical use of oral antihistamines and intranasal corticosteroids in patients with allergic rhinitis. J Investig Allergol Clin Immunol. 2011;21:363-9.
28. Anolik R, Mometasone Furoate Nasal Spray With Loratadine Study Group. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100:264-71.
29. Ratner PH, van Bavel JH, Martin BG, Hampel FC Jr, Howland WC III, Rogenes PR, et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract. 1998;47:118-25.
30. Esteitie R, deTineo M, Naclerio RM, Baroody FM. Effect of the addition of montelukast to fluticasone propionate for the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2010;105:155-61.
31. Hellings PW, Dobbels F, Denhaerynck K, Piessens M, Ceuppens JL, De GS. Explorative study on patient's perceived knowledge level, expectations, preferences and fear of side effects for treatment for allergic rhinitis. Clin Transl Allergy. 2012;2:9.
32. Ciprandi G, Incorvaia C, Scurati S, Puccinelli P, Soffia S, Frati F, et al. Patient-related factors in rhinitis and asthma: the satisfaction with allergy treatment survey. Curr Med Res Opin. 2011;27:1005-11.
33. Valovirta E, Ryan D. Patient adherence to allergic rhinitis treatment: results from patient surveys. Medscape J Med. 2008;10:247.
34. Mosges R, Klimek L. Today's allergic rhinitis patients are different: new factors that may play a role. Allergy. 2007;62:969-75.
35. Settipane RA, Lieberman P. Update on nonallergic rhinitis. Ann Allergy Asthma Immunol. 2001;86:494-507.
36. Bousquet PJ, Bachert C, Canonica GW, Casale TB, Mullol J, Klossek JM, et al. Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol. 2010;126:666-8.
37. Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK, et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin Immunol. 2009;124:S43-70.
38. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129:1282-9.
39. Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013;161:369-77.
40. Costa DJ, Amouyal M, Lambert P, Ryan D, Schunemann HJ, Daures JP, et al. How representative are clinical study patients with allergic rhinitis in primary care? J Allergy Clin Immunol. 2011;127:920-6.
41. Price D, Scadding G, Bachert C, Saleh H, Nasser S, Bichel K, et al. Dynamics of treatment within a year in patients diagnosed with either allergic, non-allergic rhinitis or hay fever over the period 1992-2012. Allergy. 2014;69:A284.
42. Klimek L, Bachert C, Mosges R, Munzel U, Price D, Virchow JC, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015;36:40-7.
43. Scadding GK, Durham SR, Mirakian R, Jones NS, Leech SC, Farooque S, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008;38:19-42.
44. UK Healthcare: The case for health benefits. http://www.ukhealthcare.org.uk/the-case-for-health-benefits. Accessed June 2015.
45. Acaster S, Ali S, Breheny K, Bachert C, Bousquet J, Price D. Treatment preferences in patients with moderate/severe seasonal allergic rhinitis: findings of a discrete choice experiment. Allergy. 2012;67:A891.
46. Bousquet J, Schunemann HJ, Fonseca J, Samolinski B, Bachert C, Canonica GW et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): The new generation guideline implementation. Allergy. 2015 [Epub ahead of print].